SCM
QNRX

Soleus Capital Management’s Quoin Pharmaceuticals QNRX Stock Holding History

Soleus Capital Management’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$480K Buy
72,730
+47,730
+191% +$432K 0.02% 83
2025
Q4 		$361K Buy
+25,000
New +$340K 0.01% 90

Other funds holding QNRX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Soleus Capital Management's QNRX Position: Q1 2026 in Review

Soleus Capital Management increased its Quoin Pharmaceuticals (QNRX) stake by 191% in Q1 2026, buying an estimated $432K and bringing the position to 72,730 shares worth $480K. The position accounts for 0.02% of the portfolio, ranked #83.

Soleus Capital Management first reported a position in QNRX in Q4 2025 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold QNRX as of Q1 2026.

  • Soleus Capital Management held 72,730 shares of Quoin Pharmaceuticals worth $480K as of Q1 2026.
  • Soleus Capital Management bought 47,730 Quoin Pharmaceuticals shares in Q1 2026, an estimated $432K.
  • Quoin Pharmaceuticals made up 0.02% of Soleus Capital Management's portfolio in Q1 2026, its #83 holding.
  • Soleus Capital Management first reported a position in Quoin Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.